{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T07:12:19Z","timestamp":1773645139705,"version":"3.50.1"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>A retrospective cohort study to analyze the effectiveness and safety of belimumab using in the initial treatment of childhood-onset systemic lupus erythematosus (cSLE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We collected clinical data from all children with a first diagnosis of cSLE admitted to our center between 1 April 2021 and 1 November 2024. Patients who initiated belimumab within 1 month of diagnosis were assigned to the belimumab group, and those who did not receive belimumab comprised the control group. Propensity score matching (PSM) was applied to balance baseline characteristics between the groups. The proportion of lupus low disease activity status (LLDAS) and remission (Definitions of Remission in Systemic Lupus Erythematosus, DORIS), the disease activity scores, laboratory tests, glucocorticoid dosage, and adverse effects during the courses of treatment in two groups were analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There were 39 cases in both the belimumab group and the control group. The belimumab group exhibited a higher proportion of patients achieving LLDAS (31\/39 vs. 14\/39, p &amp;lt; 0.001) and DORIS (18\/39 vs. 5\/39, p =0.002) compared to the control group at 12 months after treatment. Additionally, the time to achieve LLDAS and DORIS was significantly shorter in the belimumab group (log-rank p&amp;lt; 0.001). However, no statistical variances were observed between the two groups in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores, physician global assessment (PGA) scores, complement levels, negative rates of anti-double-stranded DNA (anti-dsDNA) antibodies at each follow-up interval. From the 7th to the 12th month of treatment, the daily prednisone dose in the belimumab group was lower than in the control group. After 12 months of treatment with belimumab, B cells (p&amp;lt; 0.001) and immunoglobulin G (IgG) (p&amp;lt; 0.001) showed a significant decrease from baseline. No infusion-related adverse reactions were observed in children receiving belimumab, and the infection rate did not differ significantly from the control group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Adding belimumab to initial therapy facilitates quicker disease control and expedites glucocorticoid tapering in children, which can be a new treatment strategy for cSLE.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1769627","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T06:40:18Z","timestamp":1773643218000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and safety analysis of initial treatment with belimumab in childhood-onset systemic lupus erythematosus"],"prefix":"10.3389","volume":"17","author":[{"given":"Yan","family":"Li","sequence":"first","affiliation":[{"name":"Department of Immunology, Ministry of Education Key Laboratory of Major Diseases in Children Beijing Key Laboratory of Precision Diagnosis and Treatment of Pediatric Immune Diseases, Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Immunology, Ministry of Education Key Laboratory of Major Diseases in Children Beijing Key Laboratory of Precision Diagnosis and Treatment of Pediatric Immune Diseases, Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengyue","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Immunology, Ministry of Education Key Laboratory of Major Diseases in Children Beijing Key Laboratory of Precision Diagnosis and Treatment of Pediatric Immune Diseases, Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Nephrology & Rheumatology, Xinjiang Hospital of Beijing Children\u2019s Hospital, Children\u2019s Hospital of Xinjiang Uygur Autonomous Region","place":["Urumqi, Xinjiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziwei","family":"He","sequence":"additional","affiliation":[{"name":"Department of Immunology, Ministry of Education Key Laboratory of Major Diseases in Children Beijing Key Laboratory of Precision Diagnosis and Treatment of Pediatric Immune Diseases, Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tongxin","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Immunology, Ministry of Education Key Laboratory of Major Diseases in Children Beijing Key Laboratory of Precision Diagnosis and Treatment of Pediatric Immune Diseases, Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yurong","family":"Piao","sequence":"additional","affiliation":[{"name":"Department of Immunology, Ministry of Education Key Laboratory of Major Diseases in Children Beijing Key Laboratory of Precision Diagnosis and Treatment of Pediatric Immune Diseases, Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Immunology, Ministry of Education Key Laboratory of Major Diseases in Children Beijing Key Laboratory of Precision Diagnosis and Treatment of Pediatric Immune Diseases, Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhou","family":"Shu","sequence":"additional","affiliation":[{"name":"Department of Immunology, Ministry of Education Key Laboratory of Major Diseases in Children Beijing Key Laboratory of Precision Diagnosis and Treatment of Pediatric Immune Diseases, Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxiu","family":"Mo","sequence":"additional","affiliation":[{"name":"Department of Immunology, Ministry of Education Key Laboratory of Major Diseases in Children Beijing Key Laboratory of Precision Diagnosis and Treatment of Pediatric Immune Diseases, Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiapeng","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Immunology, Ministry of Education Key Laboratory of Major Diseases in Children Beijing Key Laboratory of Precision Diagnosis and Treatment of Pediatric Immune Diseases, Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siqi","family":"Du","sequence":"additional","affiliation":[{"name":"Capital Medical University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Nephrology & Rheumatology, Xinjiang Hospital of Beijing Children\u2019s Hospital, Children\u2019s Hospital of Xinjiang Uygur Autonomous Region","place":["Urumqi, Xinjiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziweidiguli","family":"Maimaiti","sequence":"additional","affiliation":[{"name":"Department of Nephrology & Rheumatology, Xinjiang Hospital of Beijing Children\u2019s Hospital, Children\u2019s Hospital of Xinjiang Uygur Autonomous Region","place":["Urumqi, Xinjiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huawei","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Immunology, Ministry of Education Key Laboratory of Major Diseases in Children Beijing Key Laboratory of Precision Diagnosis and Treatment of Pediatric Immune Diseases, Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s12098-023-04833-0","article-title":"Systemic lupus erythematosus in children","volume":"91","author":"Chandwar","year":"2024","journal-title":"Indian J Pediatr"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2019.108274","article-title":"Juvenile-onset systemic lupus erythematosus: Update on clinical presentation, pathophysiology and treatment options","volume":"209","author":"Smith","year":"2019","journal-title":"Clin Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/ped4.12309","article-title":"The role of epigenetics in childhood autoimmune diseases with hematological manifestations","volume":"6","author":"Gkoutsias","year":"2022","journal-title":"Pediatr Investig"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1177\/0961203316644333","article-title":"Differences in disease phenotype and severity in SLE across age groups","volume":"25","author":"Ambrose","year":"2016","journal-title":"Lupus"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2021.108907","article-title":"Systemic lupus erythematosus - Are children miniature adults","volume":"234","author":"Alexander","year":"2022","journal-title":"Clin Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000621","article-title":"Update on the treatment and outcome of systemic lupus erythematous in children","volume":"31","author":"Rodriguez-Smith","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-216924","article-title":"2019 update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis","volume":"79","author":"Fanouriakis","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","article-title":"Update on the diagnosis and management of systemic lupus erythematosus","volume":"80","author":"Fanouriakis","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.2315","article-title":"Systemic lupus erythematosus: A review","volume":"331","author":"Siegel","year":"2024","journal-title":"JAMA"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S216193","article-title":"Management of pediatric systemic lupus erythematosus: Focus on belimumab","volume":"14","author":"Guzman","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217101","article-title":"Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: Results from a randomised, placebo-controlled trial","volume":"79","author":"Brunner","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211631","article-title":"A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea","volume":"77","author":"Zhang","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/0961203318804879","article-title":"The effectiveness and safety of biological therapeutics in juvenile-onset systemic lupus erythematosus (JSLE): A systematic review","volume":"27","author":"Peterknecht","year":"2018","journal-title":"Lupus"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead629","article-title":"Real-world efficacy of belimumab in systemic lupus erythematosus: A prospective cohort from a single center in China","volume":"64","author":"Zhao","year":"2025","journal-title":"Rheumatol (Oxford)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.1362","article-title":"Belimumab in early systemic lupus erythematosus: A propensity score matching analysis","volume":"12","author":"Lu","year":"2024","journal-title":"Immun Inflammation Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B17","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(22)00107-2","article-title":"Physician global assessment international standardisation consensus in systemic lupus erythematosus: the PISCOS study","volume":"4","author":"Piga","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000538","article-title":"2021 DORIS definition of remission in SLE: Final recommendations from an international task force","volume":"8","author":"Van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v042.i08","article-title":"MatchIt nonparametric preprocessing for parametric causal inference","volume":"42","author":"Ho","year":"2011","journal-title":"J Stat Softw"},{"key":"B22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41584-025-01321-x","article-title":"Insights into the pathogenesis of childhood-onset SLE in the past decade","volume":"22","author":"Robinson","year":"2026","journal-title":"Nat Rev Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1457821","article-title":"Tofacitinib for child-onset systemic lupus erythematosus","volume":"15","author":"Hou","year":"2024","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205139","article-title":"Treat-to-target in systemic lupus erythematosus: Recommendations from an international task force","volume":"73","author":"Van Vollenhoven","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1177\/09612033231208845","article-title":"Disease-modifying effect and long-term safety of belimumab in patients with systemic lupus erythematosus: A single-center retrospective study","volume":"32","author":"Nakai","year":"2023","journal-title":"Lupus"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1177\/09612033221090888","article-title":"Efficacy and safety of belimumab therapy in systemic lupus erythematosus: A systematic review and meta-analysis","volume":"31","author":"Chiang","year":"2022","journal-title":"Lupus"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.940416","article-title":"Belimumab in childhood systemic lupus erythematosus: A review of available data","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1177\/09612033231187752","article-title":"Real-world use and outcomes of belimumab in childhood-onset lupus: A single-center retrospective study","volume":"32","author":"Roberts","year":"2023","journal-title":"Lupus"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.911730","article-title":"Efficacy and safety of belimumab\/low-dose cyclophosphamide therapy in moderate-to-severe systemic lupus erythematosus","volume":"13","author":"Cheng","year":"2022","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2023.2207671","article-title":"Efficacy and safety of belimumab therapy in lupus nephritis: A systematic review and meta-analysis","volume":"45","author":"Zhang","year":"2023","journal-title":"Ren Fail"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1067721","article-title":"Efficacy and safety of belimumab for the treatment of refractory childhood-onset systemic lupus erythematosus: A single-center, real-world, retrospective study","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead406","article-title":"Evaluation of belimumab in treatment of Chinese childhood-onset systemic lupus erythematosus: A prospective analysis from a multicentre study","volume":"63","author":"Wang","year":"2024","journal-title":"Rheumatol (Oxford)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.60167","article-title":"Cost-effectiveness of early vs delayed belimumab treatment for systemic lupus erythematosus","volume":"9","author":"Hundal","year":"2026","journal-title":"JAMA Netw Open"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003981","article-title":"Analysis of belimumab prescription and outcomes in a 10-year monocentric cohort: Is there an advantage with early use","volume":"10","author":"Tani","year":"2024","journal-title":"RMD Open"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1074044","article-title":"Updates in the care and management of children and adolescents with systemic lupus erythematosus","volume":"36","author":"Silva","year":"2024","journal-title":"Curr Opin Rheumatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2024-001350","article-title":"Efficacy of initial combination with belimumab in newly diagnosed childhood-onset lupus nephritis: A single-centre historical control study","volume":"11","author":"Gong","year":"2024","journal-title":"Lupus Sci Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae495","article-title":"Efficacy, safety, and optimal intervention of belimumab for proliferative lupus nephritis patients in real-world settings: LOOPS registry","volume":"64","author":"Sakai","year":"2025","journal-title":"Rheumatol (Oxford)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2019.03.010","article-title":"Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus","volume":"49","author":"Deng","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02156-2","article-title":"Revolutionary changes in the management of lupus nephritis: Towards de-glucocorticoid or no-glucocorticoid","volume":"85","author":"Tanaka","year":"2025","journal-title":"Drugs"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1177\/09612033241238867","article-title":"Early add-on use of belimumab as induction therapy for patients with childhood-onset systemic lupus erythematosus","volume":"33","author":"Hashimoto","year":"2024","journal-title":"Lupus"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1172\/JCI38010","article-title":"The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus","volume":"119","author":"Cancro","year":"2009","journal-title":"J Clin Invest"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/art.34400","article-title":"Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus","volume":"64","author":"Stohl","year":"2012","journal-title":"Arthritis Rheum"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1769627\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T06:40:20Z","timestamp":1773643220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1769627\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":42,"alternative-id":["10.3389\/fimmu.2026.1769627"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1769627","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"article-number":"1769627"}}